Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.69 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.57 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25228921 | 0.89 | CRBN (0.70) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL30132211 | 0.88 | CRBN (0.72) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL31117059 | 0.88 | CRBN (0.72) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL30132173 | 0.88 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL25234569 | 0.88 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL25469611 | 0.88 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL24991548 | 0.88 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL24991511 | 0.88 | CRBN (0.72) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL68272 | 0.88 | CRBN (0.72) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL15128601 | 0.88 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213056-A1 | PROCESSES FOR PREPARING 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE | CELGENE CORP (US) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213056-A1 | PROCESSES FOR PREPARING 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE | DCPS, DNMT1, DPYD | CRBN 510/4885IKZF2 2854/4885GSPT1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.